The Challenges
Genetics
Current approach is blunt, focused on rare clinically actionable variants, with only a 30% yield for clinical genetic testing
Prognosis & Risk prediction
The high variability in disease expression and severity makes it difficult to identify patients at risk for heart failure and sudden cardiac death
Treatment
Limited therapeutic options which focus on generic symptom relief or invasive procedures
![](/wp-content/uploads/2024/08/Heart2-scaled.jpg)
![](/wp-content/uploads/2024/02/DNA2.jpg)
Mission
DCM-NEXT aims to develop comprehensive genetic risk profiling, predict disease outcomes more precisely, and expedite treatment development by identifying specific genes, variants, pathways, and cell types involved in DCM pathogenesis. This is crucial for addressing unmet medical needs in DCM patients globally.
Starting
1st of October 2023
Duration
48 months
Partners
7
Countries
5
Work Packages
8
Funding
€ 4.137.718,75
![](/wp-content/uploads/2024/02/EN_FundedbytheEU_RGB_POS.png)
![](/wp-content/uploads/2024/02/EIC-LOGO-2021.png)
Funded by the Call: HORIZON-EIC-2022-PATHFINDERCHALLENGES 01 “CARDIOGENOMICS” from HORIZON European Innovation Council Grants/ European Commission